Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: A 6-month follow-up study

References

• Aithal, GP , Day, CP , Kesteven, PJL , and Daly, AK , 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , Lancet 353 (9154) (1999), pp. 717–719.
   PubMed Web of Science ®Google Scholar
• Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group, 1994. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , Lancet 343 (1994), pp. 499–503.
   PubMed Web of Science ®Google Scholar
• Beyth, RJ , Quinn, L , and Landefeld, CS , 2000. A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin , Annals of Internal Medicine 133 (2000), pp. 687–695.
   PubMed Web of Science ®Google Scholar
• Bodin, L , Verstuyft, C , Tregouet, DA , Robert, A , Dubert, L , Funck-Brentano, C , Jaillon, P , Beaune, P , Laurent-Puig, P , Becquemont, L , et al., 2005. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinant of acenocoumaraol sensitivity , Blood 106 (2005), pp. 135–140.
   PubMed Web of Science ®Google Scholar
• Cannegieter, SC , Rosendaal, FR , Wintzen, AR , Van der Meer, FJ , Vandenbroucke, JP , and Briet, E , 1995. Optimal oral anticoagulant therapy in patients with mechanical heart valves , New England Journal of Medicine 333 (1995), pp. 11–17.
   PubMed Web of Science ®Google Scholar
• D’Andrea, G , D’Ambrosio, RL , Di Perna, P , Chetta, M , Santacroce, R , Brancaccio, V , Grandone, E , and Margaglione, M , 2005. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose–anticoagulant effect of warfarin , Blood 105 (2005), pp. 645–649.
   PubMed Web of Science ®Google Scholar
• Fihn, SD , McDonell, M , Martin, D , Henikoff, J , Vermes, D , Kent, D , and White, RH , 1993. Risk factors for complications of chronic anticoagulation , Annals of Internal Medicine 118 (1993), pp. 511–520.
   PubMed Web of Science ®Google Scholar
• Hirsch, J , Dalen, JE , Anderson, DR , Poller, L , Bussey, H , and Ansell, J , 1998. Oral anticoagulants: Mechanisms of action, clinical effectiveness and optimal therapeutic range , Chest 114 (1998), pp. 445S–469S.
   PubMed Web of Science ®Google Scholar
• Peyvandi, F , Spreafico, M , Siboni, SM , Moia, M , and Mannucci, PM , 2004. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy , Clinical Pharmacology and Therapy 75 (2004), pp. 198–203.
   PubMed Web of Science ®Google Scholar
• Poller, L , Shiach, CR , MacCallum, PK , Johansen, AM , Münster, AM , Magalhães, A , and Jespersen, J , 1998. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation , Lancet 352 (1998), pp. 1505–1509.
   PubMed Web of Science ®Google Scholar
• Rost, S , Fregin, A , Ivaskevicius, V , Conzelmann, E , Hörtnagel, K , Pelz, HJ , Lappegard, K , Seifried, E , Scharrer, I , Tuddenham, EG , et al., 2004. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , Nature 427 (2004), pp. 537–541.
   PubMed Web of Science ®Google Scholar
• Sconce, EA , Khan, TI , Wynne, HA , Avery, P , Monkhouse, L , King, BP , Wood, P , Kesteven, P , Daly, AK , and Kamali, F , 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen , Blood 106 (2005), pp. 2329–2333.
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators, 1996a. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , Lancet 348 (1996a), pp. 633–638.
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators, 1996b. Bleeding during antithrombotic therapy in patients with atrial fibrillation , Archives of Internal Medicine 156 (1996b), pp. 409–416.
   PubMed Web of Science ®Google Scholar
• Takahashi, H , Kashima, T , Nomizo, Y , Muramoto, N , Shimizu, T , Nasu, K , Kubota, T , Kimura, S , and Echizen, H , 1998a. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes , Clinical Pharmacology and Therapy 63 (1998a), pp. 519–528.
   PubMed Web of Science ®Google Scholar
• Takahashi, H , Kashima, T , Nomoto, S , Iwade, K , Tainaka, H , Shimizu, T , Nomizo, Y , Muramoto, N , Kimura, S , and Echizen, H , 1998b. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes , Pharmacogenetics 8 (1998b), pp. 365–373.
   PubMedGoogle Scholar
• Teh, LK , Ismail, R , Yusoff, R , Hussein, A , Isa, MN , and Rahman, AR , 2001. Heterogeneity of the CYP2D6 gene among Malays in Malaysia , Journal of Clinical Pharmacology and Therapy 26 (2001), pp. 205–211.
   PubMed Web of Science ®Google Scholar
• Zainuddin, Z , Teh, LK , Suhaimi, AWM , and Ismail, R , 2006. Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism , Journal of Clinical Pharmacology and Therapy 31 (2006), pp. 187–191.
   PubMed Web of Science ®Google Scholar